Congressional Letter on use of Bayh-Dole Act to Control Drug Prices
February 22, 2024
A letter signed by 28 members of Congress urging President Biden to reconsider a NIST proposal to use the Bayh-Dole Act to "march in," weaken patents and exert federal control over prescription drug prices.
Download Full Comments Below
Congressional letter to the President on march-in rights
A letter signed by 28 members of Congress to President Biden urging reconsideration of a NIST proposal to use the Bayh-Dole Act to "march in" and control drug prices.
Dear Colleagues,This month marks my one-year anniversary as BIO’s CEO. Like most of us in biotech, this post has been a labor of love. At no time in my 25-year career in this industry have I ever witnessed such awe-inspiring science. Today, we…
Re: BIO Comments on Office of Management and Budget (OMB) Statistical Policy Directive No. 8 North American Industry Classification System (NAICS)-Request forComments on Possible Revisions for 2027 (USBC–2024–0032)Dear Ms. Orvis,The Biotechnology…
Under the 340B program, participating manufacturers must offer 340B pricing on their covered outpatient drugs by covered entities, as a condition of having those drugs federally payable under Medicare Part B and Medicaid. Critically, Congress…
A letter signed by 28 members of Congress urging President Biden to reconsider a NIST proposal to use the Bayh-Dole Act to "march in," weaken patents and exert federal control over prescription drug prices.
A letter signed by 28 members of Congress to President Biden urging reconsideration of a NIST proposal to use the Bayh-Dole Act to "march in" and control drug prices.